A company still losing money, with high risk. Institutions are adding.
Facts from SEC filings, not a recommendation.
From MPLT's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Last 12 months: -$229.8M.
Price chart by TradingView.
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: net margin 10%+, profitable every year, share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
SEC filings of any kind. 50 means a normal week.
Institutions added 6.1% to their holdings. 57 bought, 40 sold.
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|---|---|---|---|---|---|
Anatol KreitzerChief Discovery Officer | Sell | 12K | $7.84 | $96K | 169K | Oct 15Filing ↗ |
| ||||||
Erin Pennock FoffChief Medical Officer | Sell | 15K | $8.08 | $124K | 297K | Oct 15Filing ↗ |
| ||||||
Kristopher HansonGeneral Counsel | Sell | 9K | $8.08 | $73K | 128K | Oct 15Filing ↗ |
| ||||||
James Woodruff LillieChief Scientific Officer | Sell | 12K | $8.08 | $93K | 199K | Oct 15Filing ↗ |
| ||||||
Jonathan GillisCAO and Interim CFO | Sell | 10K | $8.08 | $82K | 142K | Oct 15Filing ↗ |
| ||||||
Christopher A. KroegerChief Executive Officer | Sell | 74K | $8.08 | $595K | 1M | Oct 15Filing ↗ |
| ||||||
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
73,691 shares at $8.08 · $595K
15,355 shares at $8.08 · $124K
9,020 shares at $8.08 · $73K
11,513 shares at $8.08 · $93K
10,167 shares at $8.08 · $82K
12,248 shares at $7.84 · $96K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page